Medigen Biotechnology Corp. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 416.88 million compared to TWD 175.96 million a year ago. Net loss was TWD 47.11 million compared to TWD 116.2 million a year ago. Basic loss per share from continuing operations was TWD 0.34 compared to TWD 0.84 a year ago.
For the nine months, sales was TWD 786.7 million compared to TWD 852.24 million a year ago. Net loss was TWD 239.14 million compared to TWD 320.67 million a year ago. Basic loss per share from continuing operations was TWD 1.72 compared to TWD 2.31 a year ago.